1. Matsumoto T, Goulopoulou S, Taguchi K, Tostes RC, Kobayashi T. Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes. Br J Pharmacol. 2015 Aug;172(16):3980–4001.
2. Zhou Z, Matsumoto T, Jankowski V, Pernow J, Mustafa SJ, Duncker DJ, et al. Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: an update. Pharmacol Res. 2019 Mar;141:32–45.
3. Burnstock G. Purinergic signaling in the cardiovascular system. Circ Res. 2017 Jan 6;120(1):207–28.
4. Burnstock G, Ralevic V. Purinergic signaling and blood vessels in health and disease. Pharmacol Rev. 2013 Dec 11;66(1):102–92.
5. Nishimura A, Sunggip C, Oda S, Numaga-Tomita T, Tsuda M, Nishida M. Purinergic P2Y receptors: molecular diversity and implications for treatment of cardiovascular diseases. Pharmacol Ther. 2017 Dec;180:113–28.